Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.45 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.42 |
| ▸ | P2RY10 | O00398 | 8/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | FABP3 | P05413 | 1/20 | 0.37 |
| ▸ | GPR34 | Q9UPC5 | 3/20 | 0.37 |
| ▸ | AKT1 | P31749 | 2/20 | 0.36 |
| ▸ | AKT2 | P31751 | 2/20 | 0.36 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22778250 | 0.93 | LPAR1 (0.43) | LPAR1LPAR3PLA2G2CP2RY10LPAR2 | |
| SCHEMBL22778166 | 0.87 | LPAR1 (0.38) | LPAR1LPAR3PLA2G2CP2RY10LPAR2 | |
| SCHEMBL9237355 | 0.86 | PLA2G2C (0.37) | LPAR1LPAR3PLA2G2CP2RY10AKT1 | |
| SCHEMBL461952 | 0.85 | PLA2G2C (0.45) | LPAR1LPAR3PLA2G2CP2RY10 | |
| SCHEMBL22778213 | 0.83 | PLA2G2A (0.38) | LPAR1LPAR3LPAR2AKT1AKT2 | |
| Butyl Alcohol SCHEMBL28531921 | 0.81 | LPAR3 (0.51) | LPAR1LPAR3LPAR2 | |
| Propanol SCHEMBL28534467 | 0.81 | LPAR3 (0.50) | LPAR1LPAR3LPAR2 | |
| SCHEMBL8080988 | 0.81 | LPAR3 (0.58) | LPAR1LPAR3PLA2G2CLPAR2AKT1 | |
| Alcohol SCHEMBL28910422 | 0.80 | LPAR3 (0.49) | LPAR1LPAR3LPAR2 | |
| Methyl Alcohol SCHEMBL28536635 | 0.80 | LPAR3 (0.48) | LPAR1LPAR3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3982932-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | Dnalite Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | claimed |
| WO-2020252375-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | DNALITE THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | claimed |
| US-20240058454-A1 | BIOLOGICAL DELIVERY SYSTEMS | PARTICELLA INC (US) | 2024-02-22 | — | — | US | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4259099-A1 | BIOLOGICAL DELIVERY SYSTEMS | Particella, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230023615-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | PARTICELLA, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2022260678-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | DNALITE THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220296516-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | PARTICELLA, INC. | 2022-09-22 | — | — | US | disclosed |
| WO-2022132678-A1 | BIOLOGICAL DELIVERY SYSTEMS | DNALITE THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-3982932-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | Dnalite Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20210177982-A1 | MUCUS-PENETRATING PEPTIDES, DELIVERY VEHICLES AND METHODS OF THERAPY | DNALITE THERAPEUTICS, INC. | 2021-06-17 | — | — | US | disclosed |
| WO-2021119585-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | DNALITE THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| EP-3796892-A2 | MUCUS-PENETRATING PEPTIDES, DELIVERY VEHICLES AND METHODS OF THERAPY | Dnalite Therapeutics, Inc. (US) | 2021-03-31 | — | — | EP | disclosed |
| WO-2020252375-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | DNALITE THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177982-A1 | MUCUS-PENETRATING PEPTIDES, DELIVERY VEHICLES AND METHODS OF THERAPY | MUC1, VIP, CFTR | LPAR1 1659/4885LPAR3 1431/4885PLA2G2C 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.